Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RV3-BB
- Development stage
- Phase 3
- Lead developer
- Murdoch Children's Research Institute
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
RV3-BB is a live attenuated human neonatal rotavirus vaccine developed from the naturally occurring human neonatal rotavirus strain RV3 (G3P[6]), originally identified in healthy newborns. The vaccine is designed to be administered either as a birth dose (neonatal schedule) or starting at 6–8 weeks of age (infant schedule). It aims to provide early protection against severe rotavirus gastroenteritis by leveraging the natural adaptation of the strain to replicate in the newborn gut, even in the presence of maternal antibodies and breastfeeding. Clinical trials have shown that three doses of RV3-BB are well tolerated, immunogenic, and efficacious for preventing severe rotavirus gastroenteritis in infants. The primary mechanism is immunostimulation against rotavirus infection[1][2][4][6].
- Brand names
- Rotavali
- Other names
- RV3 BB vaccine - Bio Farma/Murdoch Childrens Research InstituteRotavirus vaccine - Bio-Farma/Murdoch-Childrens-Research-Institute
02
Targets
Host enterocyte cell-surface glycan
Beyond the preview
Go deeper on RV3-BB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RV3-BB.